OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $220,500.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 150,000 shares of the firm’s stock in a transaction on Friday, January 17th. The stock was acquired at an average cost of $1.47 per share, with a total value of $220,500.00. Following the completion of the transaction, the chief executive officer now directly owns 213,186,477 shares of the company’s stock, valued at approximately $313,384,121.19. This represents a 0.07 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost bought 125,000 shares of OPKO Health stock. The shares were bought at an average price of $1.59 per share, for a total transaction of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were bought at an average price of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The stock was bought at an average cost of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were bought at an average price of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was purchased at an average price of $1.50 per share, for a total transaction of $420,274.50.

OPKO Health Price Performance

OPK remained flat at $1.47 during trading on Friday. The company’s stock had a trading volume of 2,564,480 shares, compared to its average volume of 2,888,357. The company’s 50 day moving average price is $1.55 and its 200 day moving average price is $1.50. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.00 billion, a PE ratio of -7.74 and a beta of 1.63. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.76.

Wall Street Analysts Forecast Growth

OPK has been the subject of a number of recent analyst reports. Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, January 8th. Finally, StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday.

Hedge Funds Weigh In On OPKO Health

Several hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP raised its stake in shares of OPKO Health by 800.0% during the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after buying an additional 39,486,490 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after purchasing an additional 876,272 shares during the period. Clearline Capital LP bought a new position in shares of OPKO Health in the 3rd quarter worth $1,083,000. Squarepoint Ops LLC bought a new stake in OPKO Health in the second quarter valued at about $592,000. Finally, Barclays PLC lifted its stake in OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after buying an additional 329,870 shares during the period. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.